Changes of ascending aortic diameter after transcatheter aortic valve replacement
- VernacularTitle:经导管主动脉瓣置换术后升主动脉直径变化的研究和评价
- Author:
Kang AN
1
;
Fengwen ZHANG
1
;
Wenbin OUYANG
1
;
Donghui XU
1
;
Xiangbin PAN
1
Author Information
1. Department of Structural Heart Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China
- Publication Type:Journal Article
- Keywords:
Transcatheter aortic valve replacement;
annual dilation rate of ascending aorta;
adverse aortic events
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(11):1455-1459
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the changes of ascending aortic (AA) diameter after transcatheter aortic valve replacement (TAVR), and evaluate the safety and efficacy of TAVR in patients with AA dilation. Methods We retrospectively included 87 patients who underwent TAVR at our center from 2016 to 2019. These patients were divided into 2 groups based on the preoperative AA diameter. There were 17 patients in the AA diameter≥45 mm group (including 10 males, aged 74.4±5.6 years), and 70 patients in the AA diameter<45 mm group (including 39 males, aged 75.9±7.0 years). Results The baseline variables were similar between two groups (P>0.05). The overall device success rate was 97.7% (85/87). The median computed tomography (CT) follow-up time was 24.2±11.8 months in patients with AA diameter≥45 mm and 23.0±10.7 months in patients with AA diameter<45 mm, and the median annual dilation rate of AA were 0.36 mm/year and 0.00 mm/year, respectively. No statistical significance was observed between two groups (P>0.05). No adverse aortic events occurred during the follow-up period. Conclusion TAVR is safe and effective in patients with preoperative AA diameter≥45 mm, and the AA diameter remains stable after the procedure. Patients with preoperative AA diameter≥45 mm and AA diameter<45 mm have similar annual dilation rates.
